Tenaya Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
70
- Stock Symbol
-
TNYA
- Share Price
-
$0.29
- (As of Friday Closing)
Tenaya Therapeutics General Information
Description
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Contact Information
Website
www.tenayatherapeutics.comCorporate Office
- 171 Oyster Point Boulevard
- Suite 500
- South San Francisco, CA 94080
- United States
Corporate Office
- 171 Oyster Point Boulevard
- Suite 500
- South San Francisco, CA 94080
- United States
Tenaya Therapeutics Stock Performance
As of 20-Nov-2026, Tenaya Therapeutics’s stock price is $0.29. Its current market cap is $65.3M with 228M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.29 | $0.30 | $0.28 - $1.46 | $65.3M | 228M | 2.93M | -$0.49 |
Tenaya Therapeutics Financials Summary
As of 30-Sep-2026, Tenaya Therapeutics has a trailing 12-month revenue of $3.03M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 61,209 | 109,259 | 48,354 | 110,971 |
| Revenue | 3,032 | 0 | 0 | 0 |
| EBITDA | (98,797) | (84,843) | (107,398) | (122,440) |
| Net Income | (101,778) | (90,597) | (111,129) | (124,084) |
| Total Assets | 76,681 | 146,921 | 119,940 | 170,515 |
| Total Debt | 2,852 | 10,830 | 13,608 | 12,424 |
Tenaya Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tenaya Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Tenaya Therapeutics Comparisons
Industry
Financing
Details
Tenaya Therapeutics Competitors (56)
One of Tenaya Therapeutics’s 56 competitors is Rocket Pharmaceuticals, a Formerly VC-backed company based in Cranbury, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals | Formerly VC-backed | Cranbury, NJ | ||||
| Madrigal Pharmaceuticals | Formerly VC-backed | West Conshohocken, PA | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Sharp Therapeutics (Biotechnology) | Formerly VC-backed | Pittsburgh, PA |
Tenaya Therapeutics Patents
Tenaya Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026165422-A1 | Rbm20 gene editing systems and methods of use | Pending | 31-Jan-2025 | ||
| WO-2026156172-A2 | Biomarkers in arrhythmogenic right ventricular cardiomyopathy and methods of treatment | Pending | 16-Jan-2025 | ||
| WO-2026122463-A1 | Adeno-associated virus with engineered capsid | Pending | 02-Dec-2024 | ||
| WO-2026080860-A1 | Prime editing compositions and methods of use | Pending | 11-Oct-2024 | ||
| WO-2026080685-A1 | Guide rnas, vectors, and virions for targeting mutations in the pln gene | Pending | 10-Oct-2024 | C12N15/86 |
Tenaya Therapeutics Signals
Tenaya Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tenaya Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.02 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Tenaya Therapeutics FAQs
-
When was Tenaya Therapeutics founded?
Tenaya Therapeutics was founded in 2016.
-
Where is Tenaya Therapeutics headquartered?
Tenaya Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Tenaya Therapeutics?
Tenaya Therapeutics has 70 total employees.
-
What industry is Tenaya Therapeutics in?
Tenaya Therapeutics’s primary industry is Drug Discovery.
-
Is Tenaya Therapeutics a private or public company?
Tenaya Therapeutics is a Public company.
-
What is Tenaya Therapeutics’s stock symbol?
The ticker symbol for Tenaya Therapeutics is TNYA.
-
What is the current stock price of Tenaya Therapeutics?
As of 20-Nov-2026 the stock price of Tenaya Therapeutics is $0.29.
-
What is the current market cap of Tenaya Therapeutics?
The current market capitalization of Tenaya Therapeutics is $65.3M.
-
What is Tenaya Therapeutics’s current revenue?
The trailing twelve month revenue for Tenaya Therapeutics is $3.03M.
-
Who are Tenaya Therapeutics’s competitors?
Rocket Pharmaceuticals, Madrigal Pharmaceuticals, Regenxbio, uniQure, and Sharp Therapeutics (Biotechnology) are some of the 56 competitors of Tenaya Therapeutics.
-
What is Tenaya Therapeutics’s annual earnings per share (EPS)?
Tenaya Therapeutics’s EPS for 12 months was -$0.49.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process